TGTX vs. RKLB
TGTX (TG Therapeutics, Inc.) and RKLB (Rocket Lab USA, Inc.) are both stocks. TGTX operates in Biotechnology (Healthcare), while RKLB operates in Aerospace & Defense (Industrials). Over the past 3 years, TGTX returned 35.52%/yr vs 129.83%/yr for RKLB. At a 0.34 correlation, their price movements are largely independent.
Performance
TGTX vs. RKLB - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, TGTX achieves a 84.54% return, which is significantly higher than RKLB's 9.99% return.
TGTX
- 1D
- -3.69%
- 1M
- 11.09%
- 6M
- 98.45%
- YTD
- 84.54%
- 1Y
- 48.33%
- 3Y*
- 35.52%
- 5Y*
- 8.24%
- 10Y*
- 25.10%
RKLB
- 1D
- -5.32%
- 1M
- -25.06%
- 6M
- -12.71%
- YTD
- 9.99%
- 1Y
- 96.59%
- 3Y*
- 129.83%
- 5Y*
- —
- 10Y*
- —
TGTX vs. RKLB - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
TGTX TG Therapeutics, Inc. | 84.54% | -0.96% | 76.23% | 44.38% | -37.74% | -27.40% |
RKLB Rocket Lab USA, Inc. | 9.99% | 173.89% | 360.58% | 46.68% | -69.30% | 8.67% |
Correlation
The correlation between TGTX and RKLB is 0.22, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.22 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.31 |
Correlation (All Time) Calculated using the full available price history since Aug 24, 2021 | 0.34 |
The correlation between TGTX and RKLB shifts across timeframes, from 0.22 (1 year) to 0.34 (all time), reflecting how their relationship changes across market environments.
Fundamentals
TGTX:
$8.42B
RKLB:
$44.42B
TGTX:
$2.88
RKLB:
-$0.32
TGTX:
12.58
RKLB:
64.23
TGTX:
15.10
RKLB:
20.52
TGTX:
$700.35M
RKLB:
$679.58M
TGTX:
$581.54M
RKLB:
$248.43M
TGTX:
$156.88M
RKLB:
-$177.36M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
TGTX vs. RKLB — Risk / Return Rank
TGTX
RKLB
TGTX vs. RKLB - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for TG Therapeutics, Inc. (TGTX) and Rocket Lab USA, Inc. (RKLB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| TGTX | RKLB | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | 0.00 | ||
| Sortino ratioReturn per unit of downside risk | -0.19 | ||
| Omega ratioGain probability vs. loss probability | 1.22 | 1.22 | 0.00 |
| Calmar ratioReturn relative to maximum drawdown | 1.49 | 1.99 | -0.50 |
| Martin ratioReturn relative to average drawdown | 2.69 | 4.51 | -1.82 |
Loading charts...
Drawdowns
TGTX vs. RKLB - Drawdown Comparison
The maximum TGTX drawdown since its inception was -99.52%, which is greater than RKLB's maximum drawdown of -82.96%. Use the drawdown chart below to compare losses from any high point for TGTX and RKLB.
Loading charts...
Drawdown Indicators
| TGTX | RKLB | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.52% | -82.96% | -16.56% |
Max Drawdown (1Y)Largest decline over 1 year | -32.66% | -48.92% | +16.26% |
Max Drawdown (3Y)Largest decline over 3 years | -69.77% | -55.49% | -14.28% |
Max Drawdown (5Y)Largest decline over 5 years | -90.19% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -93.19% | — | — |
Current DrawdownCurrent decline from peak | -76.43% | -48.92% | -27.51% |
Average DrawdownAverage peak-to-trough decline | -91.36% | -51.08% | -40.28% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 18.02% | 21.51% | -3.49% |
Volatility
TGTX vs. RKLB - Volatility Comparison
The current volatility for TG Therapeutics, Inc. (TGTX) is 11.56%, while Rocket Lab USA, Inc. (RKLB) has a volatility of 31.14%. This indicates that TGTX experiences smaller price fluctuations and is considered to be less risky than RKLB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| TGTX | RKLB | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 11.56% | 31.14% | -19.58% |
Volatility (6M)Calculated over the trailing 6-month period | 34.64% | 72.33% | -37.69% |
Volatility (1Y)Calculated over the trailing 1-year period | 47.36% | 95.04% | -47.68% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 87.81% | 81.97% | +5.84% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 86.82% | 81.97% | +4.85% |
Dividends
TGTX vs. RKLB - Dividend Comparison
Neither TGTX nor RKLB has paid dividends to shareholders.
Financials
TGTX vs. RKLB - Financials Comparison
This section allows you to compare key financial metrics between TG Therapeutics, Inc. and Rocket Lab USA, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
TGTX vs. RKLB - Profitability Comparison
TGTX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, TG Therapeutics, Inc. reported a gross profit of 171.41M and revenue of 204.92M. Therefore, the gross margin over that period was 83.7%.
RKLB - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Rocket Lab USA, Inc. reported a gross profit of 76.49M and revenue of 200.35M. Therefore, the gross margin over that period was 38.2%.
TGTX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, TG Therapeutics, Inc. reported an operating income of 34.80M and revenue of 204.92M, resulting in an operating margin of 17.0%.
RKLB - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Rocket Lab USA, Inc. reported an operating income of -55.97M and revenue of 200.35M, resulting in an operating margin of -27.9%.
TGTX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, TG Therapeutics, Inc. reported a net income of 19.78M and revenue of 204.92M, resulting in a net margin of 9.7%.
RKLB - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Rocket Lab USA, Inc. reported a net income of -45.02M and revenue of 200.35M, resulting in a net margin of -22.5%.
Frequently Asked Questions
TGTX and RKLB have a correlation of 0.22, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
RKLB has higher volatility (31.14%) compared to TGTX (11.56%). In terms of maximum drawdown, TGTX dropped -99.52% vs RKLB's -82.96%.
TGTX currently has the higher Sharpe Ratio (1.03 vs 1.02), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for TGTX and RKLB
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer